Paola Coco

877 total citations
22 papers, 651 citations indexed

About

Paola Coco is a scholar working on Gastroenterology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Paola Coco has authored 22 papers receiving a total of 651 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Gastroenterology, 13 papers in Pulmonary and Respiratory Medicine and 11 papers in Hematology. Recurrent topics in Paola Coco's work include Gastrointestinal Tumor Research and Treatment (14 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Gastric Cancer Management and Outcomes (7 papers). Paola Coco is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (14 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Gastric Cancer Management and Outcomes (7 papers). Paola Coco collaborates with scholars based in Italy, Finland and United States. Paola Coco's co-authors include Paolo G. Casali, Alessandro Gronchi, A. Messina, Silvana Pilotti, Marco Fiore, Maria Stefania Lagonigro, Francesca Miselli, Deborah Mannavola, Guia Vannucchi and Paolo Beck‐Peccoz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Paola Coco

22 papers receiving 634 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paola Coco Italy	12	420	359	159	143	133	22	651
V.R. Bulusu United Kingdom	7	444 1.1×	519 1.4×	332 2.1×	62 0.4×	102 0.8×	20	662
Vanessa Tassell United States	13	654 1.6×	298 0.8×	127 0.8×	417 2.9×	105 0.8×	25	877
Nathalie Théou–Anton France	14	322 0.8×	80 0.2×	79 0.5×	362 2.5×	115 0.9×	28	666
Yanzhi Hsu United States	16	429 1.0×	199 0.6×	192 1.2×	340 2.4×	76 0.6×	42	891
Ilana Kepten Israel	7	256 0.6×	252 0.7×	116 0.7×	41 0.3×	82 0.6×	8	578
Yen‐Yang Chen Taiwan	17	241 0.6×	130 0.4×	300 1.9×	342 2.4×	54 0.4×	70	785
Laura Giannetta Italy	9	432 1.0×	95 0.3×	151 0.9×	369 2.6×	29 0.2×	21	587
Kolette D. Fly United States	8	233 0.6×	120 0.3×	69 0.4×	179 1.3×	37 0.3×	15	460
Annette Jappe Switzerland	11	242 0.6×	101 0.3×	280 1.8×	227 1.6×	41 0.3×	14	1.1k
D.G. Haller United States	12	291 0.7×	99 0.3×	176 1.1×	539 3.8×	125 0.9×	28	805

Countries citing papers authored by Paola Coco

Since Specialization

Citations

This map shows the geographic impact of Paola Coco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paola Coco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paola Coco more than expected).

Fields of papers citing papers by Paola Coco

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paola Coco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paola Coco. The network helps show where Paola Coco may publish in the future.

Co-authorship network of co-authors of Paola Coco

This figure shows the co-authorship network connecting the top 25 collaborators of Paola Coco. A scholar is included among the top collaborators of Paola Coco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paola Coco. Paola Coco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Iurlo, Alessandra, Massimo Breccia, Fabio Stagno, et al.. (2023). Full Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study. Blood. 142(Supplement 1). 4534–4534. 5 indexed citations

Breccia, Massimo, Aurelio Pio Nardozza, Valentina Perrone, et al.. (2022). The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy. Advances in Therapy. 40(3). 961–974. 4 indexed citations

Stagno, Fabio, Elisabetta Abruzzese, Alessandra Iurlo, et al.. (2022). Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study. Blood. 140(Supplement 1). 9614–9616. 6 indexed citations

Guglielmelli, Paola, Francesca Palandri, Carmine Selleri, et al.. (2021). Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI). Leukemia & lymphoma. 63(1). 189–198. 4 indexed citations

Ferrucci, Pier Francesco, Ida Minchella, Sara Gandini, et al.. (2015). Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma. Melanoma Research. 25(3). 239–245. 19 indexed citations

Italiano, Antoîne, Angela Cioffi, Paola Coco, et al.. (2011). Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib. Annals of Surgical Oncology. 19(5). 1551–1559. 47 indexed citations

Joensuu, Heikki, Filippo de Braud, Tommaso De Pas, et al.. (2011). Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. British Journal of Cancer. 104(11). 1686–1690. 54 indexed citations

Sanfilippo, Roberta, Anastasia Constantinidou, Rossella Bertulli, et al.. (2011). Sensitivity of well-differentiated/dedifferentiated liposarcoma (WD/DD) and myxoid round cell/liposarcoma (MRCL) to high-dose ifosfamide: Combined analysis from two European referral institutions.. Journal of Clinical Oncology. 29(15_suppl). 10023–10023. 2 indexed citations

Italiano, Antoîne, Angela Cioffi, Robert G. Maki, et al.. (2011). Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.. Journal of Clinical Oncology. 29(15_suppl). 10044–10044. 4 indexed citations

10.

Dileo, Palma, Sabrina Pricl, Elena Tamborini, et al.. (2010). Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: An imaging, biochemical and molecular modeling study. International Journal of Cancer. 128(4). 983–990. 17 indexed citations

11.

Fumagalli, Elena, Paola Coco, Carlo Morosi, Rossella Bertulli, & Paolo G. Casali. (2010). Sunitinib rechallenge in two advanced GIST patients after third-line anti-tyrosine kinase therapy.. Journal of Clinical Oncology. 28(15_suppl). e20519–e20519. 7 indexed citations

12.

Bertulli, Rossella, Elena Fumagalli, Paola Coco, et al.. (2009). Unusual metastatic sites in gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology. 27(15_suppl). 10566–10566. 7 indexed citations

13.

Piovesan, C., Elena Fumagalli, Paola Coco, et al.. (2009). Response to sirolimus in combination to tirosine kinase inhibitors (TKI) in three cases of PDGFRA-D842V metastatic gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology. 27(15_suppl). 10565–10565. 11 indexed citations

14.

Palassini, Elena, Elena Fumagalli, Paola Coco, et al.. (2008). Combination of PKC412 and sirolimus in a metastatic patient with PDGFRA-D842V gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology. 26(15_suppl). 21515–21515. 12 indexed citations

15.

Joensuu, Heikki, Filippo de Braud, Paola Coco, et al.. (2007). Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Annals of Oncology. 19(1). 173–177. 53 indexed citations

16.

Gronchi, Alessandro, Marco Fiore, Francesca Miselli, et al.. (2007). Surgery of Residual Disease Following Molecular-targeted Therapy With Imatinib Mesylate in Advanced/Metastatic GIST. Annals of Surgery. 245(3). 341–346. 183 indexed citations

17.

Mannavola, Deborah, Paola Coco, Guia Vannucchi, et al.. (2007). A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine Uptake. The Journal of Clinical Endocrinology & Metabolism. 92(9). 3531–3534. 172 indexed citations

18.

Joensuu, Heikki, Filippo de Braud, Paola Coco, et al.. (2006). A phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate. Journal of Clinical Oncology. 24(18_suppl). 9531–9531. 13 indexed citations

19.

Gronchi, Alessandro, Marco Fiore, Rossella Bertulli, et al.. (2005). Surgery of residual disease following imatinib mesylate in advanced gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology. 23(16_suppl). 9038–9038. 13 indexed citations

20.

Casali, Paolo G., Rossella Bertulli, Elena Fumagalli, et al.. (2004). Some Lessons Learned from Imatinib Mesylate Clinical Development in Gastrointestinal Stromal Tumors. Journal of Chemotherapy. 16(sup4). 55–58. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact